Aravive to Participate In-Person at 34th Annual ROTH Conference
March 07 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive
Officer of Aravive, will participate in an in-person fireside chat
at the 34th Annual ROTH Conference on Monday, March 14, 2022, at
8:30 am PT in HEALTHCARE VFC – Suite 2022 at The Ritz Carlton, Dana
Point, California. Dr. McIntyre and Vinay Shah, Chief Financial
Officer of Aravive, will be available for one-on-one meetings on
Monday, March 14th.
A live webcast and a replay of the presentation
will be available on Events & Presentations page of
www.aravive.com.
About AraviveAravive, Inc. is a
late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). Additional information at
www.aravive.com.
Contact:Marek Ciszewski,
J.D.Vice President, Investor RelationsMarek@Aravive.com (562)
373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024